J Korean Diabetes.  2023 Sep;24(3):135-140. 10.4093/jkd.2023.24.3.135.

2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors

• Yang YS

• KMID: 2546630
• DOI: http://doi.org/10.4093/jkd.2023.24.3.135

Abstract

To prevent cardiovascular disease (CVD), which is one of the ultimate goals in the management of patients with diabetes, it is important to control not only hyperglycemia, but also modifiable CVD risk factors such as hypertension and dyslipidemia. In addition, antiplatelet agents should be used under appropriate conditions. It is necessary to evaluate whether the patient has CVD, the degree of other complications, the presence of comorbidities or other CVD risk factors, and the duration of diabetes. In this article, I will review the revised and key points of the 8th edition of the Korean Diabetes Association clinical practice guidelines for management of hypertension and dyslipidemia and the use of antiplatelet agents in patients with diabetes.

Keyword

Cardiovascular diseases; Diabetes mellitus, type 2; Dyslipidemias; Hypertension; Platelet aggregation inhibitors; Practice guideline

Figure

• 

  Fig. 1. Blood pressure management. Adapted from the article of Choi et al. (Diabetes Metab J 2023;47:575-94) [4] under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license.

Reference

1.Park JH., Ha KH., Kim BY., Lee JH., Kim DJ. Trends in cardiovascular complications and mortality among patients with diabetes in South Korea. Diabetes Metab J. 2021. 45:120–4.

2.Kim KJ., Kwon TY., Yu S., Seo JA., Kim NH., Choi KM, et al. Ten-year mortality trends for adults with and without diabetes mellitus in South Korea, 2003 to 2013. Diabetes Metab J. 2018. 42:394–401.

3.Korean Diabetes Association. Diabetes fact sheet. 2022. Available from: https://www.diabetes.or.kr/bbs/?code=fact_sheet& mode=view& number=2499&page=1& code=fact_sheet (updated 2023 May 2).

4.Choi JH., Lee KA., Moon JH., Chon S., Kim DJ., Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023. 47:575–94.

5.Omboni S., Gazzola T., Carabelli G., Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013. 31:455–67. discussion 467-8.

6.Emdin CA., Rahimi K., Neal B., Callender T., Perkovic V., Patel A. Blood pressure lowering in type 2 diabetes: a sys-tematic review and meta-analysis. JAMA. 2015. 313:603–15.

7.Wright JT Jr., Williamson JD., Whelton PK., Snyder JK., Sink KM., Rocco MV., SPRINT Research Group, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015. 373:2103–16.

8.Buckley LF., Dixon DL., Wohlford GF 4th., Wijesinghe DS., Baker WL., Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care. 2017. 40:1733–8.

9.Zhang W., Zhang S., Deng Y., Wu S., Ren J., Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021. 385:1268–79.

10.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998. 317:703–13.

11.Hansson L., Zanchetti A., Carruthers SG., Dahlöf B., Elm-feldt D., Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998. 351:1755–62.

12.Kim HL., Lee EM., Ahn SY., Kim KI., Kim HC., Kim JH, et al. The 2022 focused update of the 2018 Korean hypertension society guidelines for the management of hypertension. Clin Hypertens. 2023. 29:11.

13.Hur KY., Moon MK., Park JS., Kim SK., Lee SH., Yun JS., Committee of Clinical Practice Guidelines, Korean Diabetes Association, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021. 45:461–81.

14.Yang YS., Kim HL., Kim SH., Moon MK. Lipid management in Korean people with type 2 diabetes mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis consensus statement. Diabetes Metab J. 2023. 47:1–9.

15.Mach F., Baigent C., Catapano AL., Koskinas KC., Casula M., Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020. 41:111–88.

16.Moon MK., Noh J., Rhee EJ., Park SH., Kim HC., Kim BJ, et al. Cardiovascular outcomes according to comorbidities and low-density lipoprotein cholesterol in Korean people with type 2 diabetes mellitus. Diabetes Metab J. 2023. 47:45–58.

17.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S158–90.

18.Masson W., Barbagelata L., Lavalle-Cobo A., Lobo M., Masson G., Nogueira JP, et al. Low-doses aspirin in the prima-ry prevention of cardiovascular disease in patients with diabetes: meta-analysis stratified by baseline cardiovascular risk. Diabetes Metab Syndr. 2022. 16:102391.